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The identification of human tumor antigens has potential utility in the diagnosis and treat-
ment of cancers. We demonstrate here a complete strategy to profile immunoreactivity and
identify tumor antigens from proteins derived from tumor cell lines. Microarrays of proteins
produced from 2-D LC fractionation of prostate tumor cell-line lysates were used to profile
immunoreactivity in the sera of prostate cancer patients and control subjects. Cancer-asso-
ciated immunoreactivity to distinct groups of chromatography fractions was present in about
50% of the patients, with greater immunoreactivity present in patients with non-organ-con-
fined cancer than in patients with organ-confined cancer. We grouped the immunoreactive
fractions by similarities in elution order and patterns of immunoreactivity to guide and
interpret the MS analysis of selected fractions, which was used to identify the proteins that
may be responsible for the immunoreactivity. As a complementary method to further charac-
terize and validate the immunoreactivity of the proteins identified by mass spectrometry, we
demonstrate the use of focused microarrays of recombinant proteins. Disease-associated
immunoreactivity was confirmed for one of the identified proteins, human Kallikrein 11.
These results demonstrate a practical approach to screening, identifying, and validating
immunoreactive proteins that could be applied to diverse studies on humoral immune
responses.
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1 Introduction
It has long been known that many types of cancers com-
monly elicit an immune response. A better understanding of
the biological significance of the immune response, its use in
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diagnosing or classifying cancers, and its potential ther-
apeutic use in treating cancers could be beneficial for cancer
patients. Knowledge of the specific tumor-associated anti-
gens and of the immune responses against those antigens is
critical for eventual research or clinical uses of the immune
response. Recently, we and other groups have demonstrated
that natural protein microarrays, in which the arrays are
spotted with multi-dimensional, liquid-based fractions of
proteins from native sources such as human cells and tis-
sues, can be a valuable screening tool for the discovery of
tumor-associated antigens [1, 2]. This report presents a
robust strategy for immune profiling using natural proteins
in arrays, combined with identification and validation of
antigens in those protein fractions.
The natural protein microarray method is com-
plementary to other strategies that have been developed for
discovering tumor antigens. Serological analysis of cDNA
expression libraries (SEREX) [3, 4] involves the construction
of a cDNA library from tumor tissue, expression in a phage
system, and panning against sera from cancer patients. This
method has been used to identify many tumor antigens [3, 5,
6]. In a recent report, microarrays of selected members of
fusion-peptide libraries were used to discover multiple auto-
antibodies associated with prostate cancers [7]. An advanta-
geous feature of natural protein arrays is that proteins are
taken from their native states, so that potentially immuno-
genic and biologically significant alterations to the proteins
may be detectable. Another method that uses proteins taken
from native states is 2-DE separations of tumor cell material
followed by Western blot analysis using patient sera. That
method has led to the identification of tumor antigens in
pancreatic [8], lung [9, 10], breast [11], colon [12], hepato-
cellular [13], and ovarian cancers [14]. Advantages of natural
protein arrays over gel blots are higher reproducibility, wider
range of proteins detected, simplified data interpretation,
and higher throughput.
Prostate cancer is an immunogenic tumor, as shown by
the identification of antibodies against many tumor-associated
antigens in prostate tumors. For example, antibodies have
been detected in serum or plasma of prostate cancer patients
against proteins such as alpha-methyl-acyl-CoA racemase
(AMACR) [15], enhancer of zeste homolog 2 (EZH2) [16], PSA
[17], HER-2/neu [17], secretory granules of the prostate [18],
and lens epithelium-derived growth factor p75 (LEDGF/p75)
[19]. The high prevalence of a tumor-associated immune re-
sponse in patients with prostate cancers was shown in a study
of a panel of six tumor-associated antigens [20] with a positive
response in cancers at 92.5% vs. 14.8% in normals, as well as
with microarrays of phage-displayed polypeptides at a speci-
ficity of 88.2% and 81.6% sensitivity [7].
A practical strategy to profile the autoantibody reactivity
from prostate cancer patients against multiple cancer-
derived proteins could better harness information from the
immune response for benefit to patients. The identification
of new tumor antigens from tumor-derived or cell-line-
derived material could lead to the development of effective
diagnostic tests or the better understanding of protein
alterations in the tumor environment. We report here such a
strategy using natural protein arrays derived from a prostate
cancer cell line, combined with improvements to identify
some of the immunoreactive proteins, with an example of
confirming such identification for one protein using a
focused microarray.
2 Materials and methods
2.1 Serum samples
Serum samples were collected as part of a HIPAA-compliant,
IRB-approved, National Cancer Institute-sponsored protocol
(through the Early Detection Research Network) at the Johns
Hopkins Medical Institution. Samples were collected prior to
a prostate biopsy or prostatectomy that had been dictated by
an elevated prostate-specific antigen (PSA) concentration
(.4.0 ng/mL) and/or an abnormal digital rectal examination
(DRE). Patients with biopsy-confirmed cancer underwent
radical retropubic prostatectomy. The tumors were mostly
Gleason grade 6 or 7. The cancers were classified as organ-
confined or non-organ-confined based on the surgical
pathology. The cancers in the non-organ-confined class had
capsular penetration and, in a few cases, lymph node and
seminal vesicle involvement. Control sera were collected
from age-similar men with normal serum PSA levels and a
negative DRE as part of a routine community-screening
program. The demographic information from the control
group was statistically similar to the patient groups. A sum-
mary of the sample numbers, age of patients, and PSA values
of the samples is given in Table 1. The samples were stored
frozen at 2807C and shipped frozen on dry ice to the Van
Andel Research Institute.
2.2 Cell culture and protein extraction
The LNCaP cell line (ATCC, Manassas, VA), which is a
metastatic prostate cancer cell line, was cultured in RPMI
1650 medium supplemented with 10% FCS (Invitrogen,
Carlsbad, CA). Approximately 50 mg of protein was extracted
by solubilizing the cells in a lysis buffer of 6 M urea, 2 M
thiourea, 1.0% n-octyl beta-D-glucopyranoside, 2 mM
dithioerythritol, protease inhibitor cocktail (Roche, Basel,
Switzerland), and 2% carrier ampholytes, pH 3.5–10 (Bio-
Rad, Hercules, CA). We collected protein from 12 P100 cul-
ture dishes containing approximately 9.56106 cells/plate,
resulting in approximately 50 mg of protein. The protein
extract was stored at 2807C until ready for use.
2.3 Protein fractionation
The cell lysates were fractionated by 2-D LC. The first di-
mension of separation was liquid phase IEF using a pre-
parative scale Rotofor (Bio-Rad) to collect 20 fractions, start-
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Table 1. Samples used in the experiments
Profiling experiments (sets 1, 2, and 3)
Class Number Age (SD) PSA (SD)
Healthy control 46 55 (6.5) 0.7 ng/mL (0.48)
Non-organ-confined
prostate cancer
51 60 (6.5) 6.3 ng/mL (5.74)
Organ-confined
prostate cancer
50 57 (6.4) 5.2 ng/mL (2.49)
Focused arrays
Class Number Age (SD) PSA (SD)
Healthy control 66 54 (6.4) 0.7 ng/mL (0.52)
Non-organ-confined
prostate cancer
69 60 (6.4) 6.5 ng/mL (5.28)
Organ-confined
prostate cancer
70 57 (6.4) 5.1 ng/mL (2.46)
ing from 50 mg of protein. Each of the fractions was further
separated by RP-HPLC in the second dimension. Separa-
tions were performed on an R2/20 RP column (Applied Bio-
systems, Foster City, CA) using a gradient of water and ACN
(buffer A: 98% H2O/2% ACN/0.1% TFA; buffer B: 10%
H2O/90% ACN/0.1% TFA) at a flow rate of 3 mL/min. The
gradient profile used was as follows: (i) 90% A to 80% A in
2.5 min; (ii) 80% A to 30% in 55 min; (iii) 30% A to 0% A in
2.5 min. Eighty-four RP fractions were collected for each of
the 20 first-dimension fractions. The resulting 1680 fractions
were collected into 20 96-well microtiter plates (1 plate for
each of the first-dimension collections) and lyophilized to
dryness. Each fraction was resuspended in 35 mL PBS
(137 mM NaCl; 2.7 mM KCl; 10.1 mM Na2HPO4; 1.8 mM
KH2PO4). An estimated average of 3.5 mg of protein was col-
lected in each fraction, resulting in a 100 mg/mL average
protein concentration in the resuspensions.
2.4 Microarray production and use
The resuspended 1680 fractions and controls [PBS, anti-
human IgG (biotinylated and not), anti-IgM, anti-Albumin,
PSA, and Tetanus Toxoid] were printed in duplicate spots on
NC-coated slides (Schleicher and Schuell, Keene, NH) using
a custom-built contact printer that was an enhanced version
of an earlier contact printer design [21]. The microarrays
were printed in three successive batches, with each batch
used for a separate experiment set. After printing, the slides
were stored vacuum-sealed with desiccant at 47C until use.
Each array was circumscribed with a border that was
applied by hand using a hydrophobic marker (Super HT Pap
Pen, Scientific Devices Laboratory, Des Plaines, IL). The
arrays were rinsed for 30 s in PBS with 0.5% Tween 20
(PBST0.5) then washed three times with gentle rocking for
3 min in fresh changes of PBST0.5. The slides were blocked
in 1% BSA in PBST0.5 for 2 h at room temperature with
gentle shaking. Each serum sample was diluted 1:60 in
PBST0.1. In the first two experiment sets, the diluent con-
tained 2 mg/mL dinitrophenol-labeled BSA (labeled using N-
hydroxysuccinimide-DNP, Invitrogen) and 1 mg/mL flag-
labeled bacterial alkaline phosphatase (Sigma) as controls.
Three hundred microliters of each diluted serum solution
was incubated on an array for 90 min at room temperature
with gentle shaking. The arrays were rinsed and washed
three times, 5 min each, in PBST0.1. Biotinylated anti-
human Ig (Amersham Biosciences) (5 mg/mL) in 3% non-
fat milk/PBST0.1 was incubated on the arrays for 1 h with
gentle shaking followed by three 5-min washes with
PBST0.1. Streptavidin-phycoerythrin (Amersham Bio-
sciences) (10 mg/mL) in 3% nonfat milk/PBST0.1 was incu-
bated on each array for 1 h with gentle shaking. The micro-
arrays were washed three times, 5 min each, with PBST0.1
and dried by centrifugation at 1506g for 3 min.
The microarrays were scanned for fluorescence with a
microarray scanner (ScanArray, Perkin Elmer Life Sciences,
Boston, MA) using a green laser (543 nm) set to consistent
detector gain and laser power settings for all slides. The
images were analyzed using the GenePix Pro 5.0 (Axon
Instruments) software program. The background-subtracted
intensities of duplicate spots were averaged using the geo-
metric mean. Hierarchical clustering and visualization were
performed using the Cluster and Treeview programs (see
http://rana.lbl.gov/). The M2 statistics [22] was calculated in
Microsoft Excel. For each fraction, the M2 score was the
number of samples within a patient group that had intensity
above a threshold, defined as the second-highest intensity in
a control group of samples.
2.5 MS
Prior to analysis by MS, the proteins in the fractions to be an-
alyzed were digested in a 1/10 volume of ACN and 1 mL of MS
grade Trypsin Gold (Promega) at a concentration of 20 ng/
mL. The digested fractions were stored at –807C until analysis.
Two MS methods were used to analyze the digested proteins.
At the Michigan State University Proteomics Facility
(http://www.proteomics.msu.edu/), the digested fractions
were analyzed by nano-scale LC/MS/MS using a Surveyor
HPLC system connected to a Linear Ion Trap Quadrupole
Fourier Transform (LTQ-FT, Thermo Electron). The digested
peptides were trapped on a homemade 100 mm65 mm
nano-trap packed with Magic C18AQ 5 mm packing material
(Michrom Bioresources). After the peptides were trapped,
they were eluted with a gradient of 2%B to 40%B in 25 min
(40 min total analysis time per sample) (A = 0.1% formic
acid, B = 100% ACN, 0.1% formic acid) on a
75 mm6100 mm picofrit column (New Objectives) packed
with Magic C18AQ. Mass spectra were acquired with the
following instrument parameters: the top eight ions were
isolated and analyzed with the FT detector (1–2 ppm accura-
cies) while simultaneously being fragmented in the LTQ to
obtain MS/MS data (200–400 ppm accuracies). Peak lists
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
Proteomics Clin. Appl. 2007, 1, 494–505 497
were extracted using “extract_msn” and searched using the
X!Tandem search algorithm (Beavisinformatics). Identifica-
tions were considered correct if the protein score had a
probability score of 23.0 or below. False positive identification
rates were determined by reversing the ensemble human
database and using X!Tandem modified Probit algorithm
built into X!Tandem. Estimated false positives and reversed
sequence false positives were zero when the minimum pro-
tein log(e) score was 23.0 or below. Proteins with fewer than
two peptides identified were verified using the verification
tool on the global proteome machine (www.thegpm.org).
At the Proteome Mapping Core at the University of
Michigan (http://www.proteomeconsortium.org/), the tryp-
sin-digested protein fractions were subjected to RP capillary
HPLC on an Agilent 1100 instrument using a Zorbax SB-
C18, 15060.1 mm column at a flow rate of 400 nL/min. In
total, 224 fractions were collected on a MALDI plate using an
Agilent MALDI fraction collector with online addition of
CHCA (2 mg/mL containing 10 mM ammonium phosphate
in 50% isopropanol, 1% acetic acid). Plates were subjected to
MS/MS analysis on an Applied Biosystems model 4700
MALDI TOF-TOF MS/MS spectrometer. Acquisition of data
was under 4000 series Explorer software using results-de-
pendent acquisition with MS/MS run on ions at their peak
intensities. The peak lists were searched through the
NCBInr human sequence database using GPS 3.0 (MAS-
COT v1.9-based). Consolidations of protein identifications
were performed manually.
2.6 Focused protein microarrays
Recombinant human Kallikrein 11 (hK11) isoform 1 protein
was purchased (R&D Systems, 1595-SE), and recombinant
hK11 isoform 2 protein and anti-hK11 polyclonal antibody
were obtained from the laboratory of Dr. Elephtherios Dia-
mandis at the University of Toronto. The proteins were pre-
pared at 0.5 mg/mL in PBS and were assembled in a poly-
propylene 384-well microtiter plate (MJ Research), along
with the proteins BSA, human IgM, human IgG, alpha-1-
antitrypsin, C-reactive protein, PSA, IGF-2, and carcino-
embryonic antigen. A piezoelectric non-contact printer (Bio-
chip Arrayer, Perkin Elmer) spotted approximately 350 pl of
each protein solution on the surfaces of ultra-thin-NC-coated
microscope slides (PATH slides, GenTel Biosurfaces). Ultra-
thin NC was used here instead of thick NC because less
binding capacity is needed for purified protein solutions
than for the lysate fractions described above. The thin NC is
otherwise preferable because it has a lower auto-fluorescent
background relative to the thick NC. Forty-eight identical
arrays were printed on each slide, with each 1.561.5 mm
individual array consisting of 12 proteins spotted in tripli-
cate. The slides were imprinted with a wax border around
each of the arrays to define hydrophobic boundaries, using a
custom-built device. This device, described in more detail
elsewhere [23], prints wax lines on a slide in precise loca-
tions, and its use was necessary in this application since the
hand-application of hydrophobic lines using a marker is not
precise enough for the small and tightly-spaced arrays used
here. The slides were rinsed briefly in PBST0.5, blocked for
1 h at room temperature in PBST0.5 containing 1% BSA,
and rinsed two more times with PBST0.5. Slides were dried
by centrifugation at 1506g for 3 min prior to sample appli-
cation. The serum samples were diluted 1:5 into PBST0.1,
and 7 mL of each sample was pre-incubated for 1 h at room
temperature on a blank PATH slide, which had been blocked
in PBST0.5 containing 1% BSA. The pre-incubation of the
sample on NC was found to be important in reducing non-
specific binding in the experiments. Six microliters of each
sample was removed from the preincubation slide and incu-
bated on a protein microarray with gentle rocking at room
temperature for 1 h. The slides were then processed as
described above.
3 Results
3.1 Profiling tumor immunoreactivity using
microarrays of tumor-derived proteins
Three sets of experiments were performed to probe for the
presence of tumor-reactive antibodies in the sera of prostate
cancer patients and controls. The first two were duplicates of
each other, using serum samples from patients with non-
organ-confined prostate cancer (n = 51) and from healthy
subjects (n = 46); the third used serum samples from
patients with organ-confined prostate cancer (n = 50) and
from the same healthy subjects (n = 46) (Table 1). Each of the
three experiment sets used a distinct batch of microarrays,
each batch printed on a different day. Each serum sample
was incubated on an array containing the fractions of a 2-D
separation of tumor-cell-line proteins, and the amount of Ig
binding to each fraction was quantified.
The overall reproducibility of the assay was examined by
comparing the results from the duplicate experiment sets
(one and two). A correlation coefficient (r) was calculated be-
tween the data from each array in experiment set one and the
corresponding array (incubated with the same sample) in
experiment set two (excluding data from the control spots).
Fifty-seven of the 100 arrays had correlations of over 0.9 be-
tween the experiment sets, and all but two had correlations
over 0.8, showing a high level of reproducibility (Supporting
Fig. 1A). Correlation coefficients also were calculated be-
tween each fraction in experiment set one and the corre-
sponding fraction in experiment set two for the data over all
the samples. The correlations in this case averaged around
0.7, with a range of 0.1–0.99 (Supporting Fig. 1B). The lower
average correlations for the fractions are due to the fact that
some fractions showed very little antibody binding. Negative
control arrays, in which PBS buffer was incubated instead of
serum, showed no anti-human-Ig binding (Supporting
Fig. 2).
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Figure 1. Scatter and box plots
of signal intensities. The inten-
sities of antibody binding to the
indicated fractions is shown for
the cancer samples (left in each
plot) and the control samples
(right in each plot), in which
each point is an individual sam-
ple. The box in each plot indi-
cates the upper and lower quar-
tiles, with the line in the box
indicating the median value.
Panels (A–C) present data from
non-organ-confined cancer
patients, and panels (D–F) pres-
ent data from organ-confined
cancer patients. The dashed line
in panels (A–F) indicates the
level of the second-highest con-
trol sample, and the M2 score
indicates the number of cancer
samples above that threshold.
The dashed line in panels (G)
and (H) indicates the level of the
second-highest cancer sample,
and the M2 score indicates the
number of control samples
above that threshold. The two
fractions with the highest M2
scores calculated in that way are
shown.
3.2 Identifying fractions with cancer-associated
immunoreactivity
We compared the levels of antibody binding to each of the
fractions between the cancer samples and the control sam-
ples in order to identify those fractions most likely to contain
cancer antigens. Because antibody reactivity is normally
present only in a subset of patients, with a non-normal dis-
tribution, we used the M2 statistics [22] to pick out the frac-
tions with potential cancer-associated reactivity. For each
fraction, a threshold is defined as the second-highest level of
reactivity among the control patients. The M2 statistics
counts the number of cancer patients above that threshold
(Fig. 1). Figure 1 shows the distributions of signal intensities
for the fractions with the top three M2 scores for the non-
organ-confined (M2 ranging from 12–15) and the organ-
confined samples (M2 ranging from 15–17). To get some
idea of the M2 scores that would be produced by chance, one
may define a threshold as the second-highest cancer sample
and count the number of normal samples above that thresh-
old. The M2 scores for the control samples are minimal (top
values 3 and 3) and are similar to what would be expected by
chance [22]. This analysis shows a higher level of immuno-
reactivity in the cancer samples as compared to the control
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samples for certain fractions. Many other fractions had high
M2 scores when counting the number of cancer samples
exceeding a threshold defined by the controls samples, as
shown by the distributions of M2 scores shown in Support-
ing Fig. 3. The fact that the results were reproducible in two
completely randomized experiment sets, and that the cancer-
associated immunoreactivity was observed in only a subset of
the fractions, strongly suggest that these results were not the
result of systematic bias in the data.
3.3 Defining groups of fractions containing common
immunoreactive proteins
Having identified individual fractions that may contain
tumor antigens, our next goal was to develop a method to
define the groups of fractions that may contain common
immunoreactive proteins. Because the 2-D LC separation
does not completely resolve the component proteins of a cell
lysate, each protein may be eluted in multiple, sequential
fractions. A method to identify groups of fractions that con-
tain the same immunoreactive protein could help to guide
the further analysis of those fractions and the identification
of the immunoreactive proteins. Two pieces of information
were used to define which fractions contain a common
immunoreactive protein. One was the order of the elution of
the fractions, and the other was the pattern of reactivity over
the samples. Fractions that share a common immuno-
reactive protein should have eluted in adjacent chromato-
graphy fractions, and they should share the same pattern of
reactivity over all the samples.
To visualize how the immunoreactive fractions grouped
in the chromatography order, the M2 scores of all the frac-
tions were arranged by order of separation, with the hor-
izontal axis representing the IEF dimension and the vertical
axis representing the RP chromatography dimension
(Fig. 2). Clusters of high M2 scores appear for both the non-
organ-confined (A) and the organ-confined samples (B). The
observation of clusters of reactivity is consistent with the
elution of immunoreactive proteins over several adjacent
fractions. About seven clusters of highly reactive fractions
Figure 2. Locations of M2 scores in the fractionation. Each box represents a chromatography fraction, with all the boxes arranged by elu-
tion order. The 20 columns represent the IEF first dimension, and the 84 rows represent the RP-HPLC second dimension. The intensity of
each box indicates the M2 score of each fraction (indicated by the color bar, log base 2). The colored outlines show the 60 fractions with the
highest M2 scores in each fraction, which are also colored and labeled by clustered groups (also corresponding to the clusters shown in
Fig. 3). (A) M2 scores for non-organ-confined cancer relative to controls, counting only samples that passed the threshold in both experi-
ment sets one and two. Only M2 scores above 3 are shown, and the rest are blanked for clarity. (B) M2 scores for organ-confined cancer
relative to controls in experiment set three. Only M2 scores above four are shown, and the rest are blanked.
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appear in each graph, as defined by the 60 fractions with the
highest M2 scores (highlighted in the graphs). Each of the
clusters was numbered, with clusters that were common be-
tween the organ-confined and non-organ-confined samples
given the same number. Immunoreactivity was observed
only from fractions obtained in the first half of the RP
separations (Figs. 2A and B). The hydrophobic fractions of
the second half of the RP elution probably were not soluble
in the aqueous resuspension buffer and therefore most likely
were not spotted onto the arrays.
Next, we examined the patterns of reactivity of the adja-
cent fractions. Fractions that contain a common immuno-
reactive protein should have similar patterns of reactivity
over all the samples. The patterns of reactivity over all the
samples of the 60 fractions in each experiment set with the
highest M2 scores (highlighted in Fig. 2) were visualized by
clustering (Fig. 3). The fractions clustered according to loca-
tion in the fractionation, meaning that fractions close to each
other in the fractionation also have similar patterns of reac-
tivity over all the samples. For example, all the fractions of
group 5 (yellow) have a similar pattern to each other and a
completely different pattern from all the fractions of group 1
(green). Therefore, the fractions within each group likely
share common immunoreactive proteins and the different
groups contain different immunoreactive proteins. Some
groups share similar patterns, such as groups 7, 2a, 6a, and
1a in Fig. 3A, so the same protein may be reactive in these
groups. The adjacent fractions had been spotted in distinct
regions of the microarrays, so the clustering of reactivities
was not due to spatial bias on the arrays.
The clusters gave some indication of the distribution in
the amount of total immunoreactivity in the patients. This
information is useful to predict how common this immuno-
reactivity is likely to be in a broader population of cancer
patients, and how useful a biomarker based on these anti-
gens might be. About 50% of the patients had reactivity with
seven or more of the fractions, whereas only 6% of the con-
trols had the same level of immunoreactivity. Since the pat-
terns of immunoreactivity are distinct between the different
groups, a panel of markers based on these different reactiv-
ities would perform better than measuring reactivity to any
one protein. The actual diagnostic performance will need to
be tested using purified proteins, rather than chromato-
graphy fractions, and additional samples.
3.4 Identification of proteins in the immunoreactive
fractions
The ability to group the fractions according to clusters that
each likely contains a common immunoreactive protein guid-
ed the selection of fractions for protein identification by MS
and the eventual interpretation of the data. We chose several
fractions from each of the groups of Fig. 2 (57 fractions total)
for analysis by LTQ-FT-MS. Five of the 57 fractions also were
analyzed by MALDI-MS/MS to provide information on the
depth of protein identification provided by each method. The
entire volume of each fraction not used for making micro-
arrays was consumed in the MS/MS analysis (typically 8 mL),
in order to optimize the potential for accurate identifications.
There were 1289 high-confidence protein identifications
made, with 0 to 66 proteins per fraction and 546 unique pro-
teins identified. No correlation was observed between num-
ber of proteins identified and location in the fractionation.
There were 266 proteins identified in only 1 fraction, 131
were found in 2 fractions, 46 were found in 3 fractions, and
the remaining 103 in 4 or more, whereas, 1 protein (nucleo-
lin) was found in 16 fractions. Some proteins were found in
many different groups, up to seven different groups, across
the entire separation, and others were tightly clustered
within one group. For example, the protein tubulin-specific
chaperone A was identified in 4 fractions from three differ-
ent, well-separated groups, but the protein 14-3-3 gamma
was found in 5 different fractions that were all within the
group 6a. Therefore, it appears that the resolution of the
separations was protein dependent. A complete list of all
proteins identified is given in Supporting Table 1.
Fractions within the same group usually shared many of
the same protein identifications, which would be expected
since those fractions were close in the elution order. For
example, in the four fractions from group 4 of Fig. 2A (frac-
tions p12b5, p12b6, p10b3, p11b3), 23 to 53 proteins were
identified in each fraction by either LTQ-FT-MS or MALDI-
MS/MS, and almost all of those were found in at least two of
the four fractions, with 11 proteins identified in all four
fractions. These observations agreed qualitatively with gel
electrophoresis analysis of some of the fractions, which
showed the presence of multiple protein bands and similar
band patterns between adjacent fractions. Only up to about
15 bands were observable by electrophoresis, showing the
higher resolving power and sensitivity of MS (data not
shown).
The analysis of five fractions by the two MS methods
allowed a comparison of the identified proteins between
those methods. In the analysis of three fractions from group
4 (p11B3, p10B3, p12B6), 4 proteins were found only by LTQ-
FT-MS, 11 proteins were found only by MALDI-MS/MS, and
22 were found by both techniques. In fraction p3b9, the same
single protein, heterogeneous nuclear ribonucleoprotein A2/
B1 (HNRPA2B1), was found by each method, and in fraction
p4a9, 6 and 8 proteins were found by MALDI-MS/MS and
LTQ-FT-MS, respectively, with 2 proteins found in common.
Therefore, many proteins were found by both methods, but
some unique identifications were obtained. These results
emphasize the advantage of using multiple methods to ob-
tain the most comprehensive protein identifications.
The selection of adjacent fractions likely to contain a
common immunoreactive protein presented a strategy for
narrowing the list of the best candidate antigens. We rea-
soned that the best candidates would be found in multiple
fractions within a single group, not spread out across multi-
ple groups. Poorly resolved proteins, found in multiple
groups of the separation, would not produce high and
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Figure 3. Clusters of fractions and samples. The 60 fractions with the highest M2 scores (from Fig. 2) were clustered (unsupervised aver-
age-linked) by reactivity in each sample. Each column represents data from a given sample, and each row is data from a given fraction. The
labels of the cancer samples are colored red, and the labels of the control samples are colored blue. The groups of fractions are color-coded
and numbered according to the labeling of Fig. 2. A filled-in box indicates a given sample passed the M2 threshold for a given fraction, and
a blank box indicates that it did not. (A) Non-organ-confined cancer samples and control samples (from experiment sets one and two). A
filled-in box indicates that a sample passed the M2 threshold in both experiment sets for that fraction. (B) Organ-confined cancer samples
and control samples (from experiment set three).
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tightly-cluster reactivity in one group of the fractionation.
Therefore, we reduced our candidate search to proteins that
were found in more than one fraction from only one group.
Ninety-six proteins from the LTQ-MS/MS analysis and 11
more from the MALDI analysis met these criteria. Each
group contained some candidates. When restricting the
search to proteins found in three or more fractions from only
one group, 21 proteins from the LTQ-MS/MS analysis and
one more from the MALDI analysis were found. The protein
candidates meeting these criteria are listed in Supporting
Table 2.
3.5 Validation using focused protein arrays
Since the highly multiplexed screening method presented
above may provide many candidate tumor antigens, it is
important to have a complementary method to efficiently test
and validate the candidates. We investigated the use of
smaller, more focused microarrays of recombinant proteins
to validate the immunoreactivity found in the broad screens
above. In contrast to the arrays used in the screens, which
contained thousands of spots and were printed with one
array per microscope slide, the focused arrays contained just
a few dozen spots each, with 48 arrays printed on each
microscope slide. This format allowed the high-throughput
analysis of many samples on selected proteins.
The group of fractions with the highest immuno-
reactivity (group 4 in Fig. 2) was also the smallest group,
made up of only four fractions. The hK11 was the only pro-
tein identified from that group found in all the fractions an-
alyzed by MALDI-MS/MS but not identified in any other
group. Increased expression levels of hK11 were previously
associated with prostate cancer [24]. The hK11 was therefore
considered one of the strong candidate antigens, and because
recombinant versions of the protein were available, we chose
it to demonstrate the use of focused arrays for candidate
validation.
Focused microarrays containing both isoforms 1 and 2 of
this protein were made to test the antibody reactivities to
these proteins in 209 serum samples from three patient
classes: 66 healthy controls, 70 organ-confined prostate can-
cer, and 73 non-organ-confined prostate cancer. Incubation
of the arrays with anti-human hK11 confirmed the immu-
noreactivity of the spotted hK11 (Fig. 4A), and a negative
control array (no serum) confirmed a lack of nonspecific
binding of the detection reagents (Fig. 4B). The incubations
of the cancer and control samples (representative images
shown in Figs. 4C and D) showed antibody binding to the
spotted proteins. Of all the proteins on the array, only hK11
isoform 2 had significantly different (p,0.05) binding levels
between any of the patient classes. The hK11-reactive anti-
bodies were more prevalent in the cancer patient samples
relative to the controls (Fig. 4F). The hK11-reactive antibody
levels measured in a repeat experiment using 23 samples
showed good agreement with the first set (correlation of 0.87
between sets, data not shown). Receiver-operator character-











1 p5A3 3 1 0
1 p4A3 1 1 0
1 p7A3 34 8 2
1 p8A3 18 8 2
1 p12A6 50 1 0
1 p12A7 3 1 0
1 p10A10 3 2 0
1 p11A10 4 2 0
1 p10A11 3 0 0
1 p11A11 1 0 0
2a p16A7 15 3 0
2a p17A7 32 24 6
2a p18A7 53 27 7
2a p18A9 42 19 6
2a p15A10 0 0 0
2a p17A10 11 9 0
2a p17A9 10 10 4
2a p18A12 23 7 0
2a p16A12 5 0 0
2b p17B10 61 19 4
2b p17B11 61 18 4
3a p10C8 11 7 4
3a p10C9 4 4 2
3a p9C8 44 13 4
3a p9C7 46 13 4
3a p10C7 29 7 4
3b p9C3 65 13 3
3b p8C1 31 12 3
3b p8C2 28 14 6
3b p8B1 63 3 0
4 p12B5 22 9 3
4 p12B6 13 9 2
4 p12B6* 38 16 8
4 p10B3 25 24 6
4 p10B3* 43 20 11
4 p11B3 19 23 6
4 p11B3* 42 22 11
5 p17B2 62 22 7
5 p18B2 61 22 7
6a p5A9 2 2 1
6a p4A9 8 2 1
6a p4A9* 6 3 1
6a p4A8 33 2 2
6a p1A9 3 1 0
6a p1A10 8 0 0
6a p1B10 22 3 1
6a p1B11 2 1 0
6a p2B11 20 12 2
6a p3B11 36 22 5
6a p4B11 38 21 4
6a p5B11 33 14 3
6b p3B9 1 0 0
6b p3B9* 1 0 0
6b p4B7 46 21 4
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6b p4B8 57 21 4
6b p3B8 0 0 0
No section p13A1 0 0 0
No section p14A1 0 0 0
No section p12A3 8 0 0
No section p1D10 9 0 0
No section p1D11 1 0 0
No section p12A2 8 0 0
a) The asterisks (*) indicate the fractions that were analyzed by
MALDI-MS/MS. All others were analyzed by LTQ-FT-MS. The
total number of proteins identified in each fraction is given,
followed by the number of proteins in each fraction that were
found elsewhere in the group, followed by the proteins found
in at least two fractions in a group but not found in any other
group (the candidate antigens).
istic analysis showed that hK11-reactive antibodies dis-
tinguished between all cancer and the healthy controls with
an AUC of 0.84 with a sensitivity of 93% and a specificity of
68% (Fig. 4G).
4 Discussion
We have demonstrated a complete strategy for identifying
immunoreactive proteins using natural protein microarrays
of cell-line-derived proteins. This strategy included the broad
screening of many samples; identifying groups of proteins
that contain common immunoreactive proteins; MS identi-
fication of the common proteins most likely accounting for
the immunoreactivity; and the illustrative validation of a
selected protein candidate using focused microarrays of
recombinant proteins. Because the instrumentation for pro-
ducing the proteins and preparing and using the microarrays
is relatively straightforward, the technology could be readily
adopted in other labs and applied to the study of other dis-
eases that exhibit autoimmunity. Instrumentation for auto-
mating 2-D liquid-phase separations is now available, and
fractionation services are offered on a contract basis. This
approach was effective in identifying groups of fractions with
prostate-cancer-associated immunoreactivity and in validat-
ing the disease-associated immunoreactivity of hK11.
Several groups of immunoreactive fractions were found.
Each group was reactive in up to about 30% of the patients,
and about 50% of the patients had reactivity to at least one of
the groups. Since the reactivity patterns of the different
groups were non-redundant, the proteins responsible for the
reactivities potentially could be used together to improve di-
agnostic performance relative to individual proteins. The
testing of additional cell lines and tissues may reveal
immunoreactivity in a higher percentage of patients than
observed here, which could further advance the diagnostic
potential of the method. Another extension of this method
would be to use proteins derived from actual tumor tissues,
which could more accurately reflect the alterations in tumor
proteins in comparison to cell lines. The actual application of
a diagnostic device would use purified proteins, rather than
chromatography fractions, so these analyses only estimate
the eventual diagnostic performance.
An interesting observation from the profiling of the
patient sera was the apparently lower level of immuno-
reactivity in the patients with non-organ-confined cancer,
relative to patients with organ-confined cancer. This effect
could relate to tumor-induced immunosuppression that
allows the cancer to advance [25] or could in some cases
simply indicate a weak immune response due to other rea-
sons. Since the levels of tumor-infiltrating lymphocytes can
be prognostic for prostate cancer progression [26], it may also
be valuable to look at the prognostic value of anti-tumor
antibody levels, or the relationship between circulating anti-
body levels and tumor-infiltrating lymphocyte levels.
The MS analysis of the fractions revealed apparent pro-
tein-dependent patterns of resolution, since some proteins
were found throughout the fractionation, probably reflecting
multiple isoforms, while others were tightly clustered. The
tightly clustered proteins were considered better candidates
as immunoreactive proteins, as they would be more likely to
yield measurable reactivity in one cluster of fractions. That
analysis yielded multiple candidate proteins per group and
highlighted an area for future improvement in the technol-
ogy. The separations used for this project were not optimized
for resolution, as a large amount of protein (50 mg) was
loaded onto the first dimension, and the IEF system used
here does not have the resolution of the chromatofocusing
systems now available [27]. Higher resolution separations,
perhaps combined with pre-separation of sub-cellular com-
ponents, should reduce the complexity to a handful of pro-
teins per fraction and simplify the identification of candidate
proteins. Another improvement to the method would be
better resuspension and spotting of the hydrophobic frac-
tions, which apparently were not resuspended and spotted
because of the aqueous buffer used. Buffers containing
organic solvents could be used just for those fractions, so
long as the solvents do not interfere with the microarray
analysis. The hydrophobic proteins could be important in
tumor antigen studies, because membrane-bound proteins,
especially those on the cell surface, can be important in the
aberrant function and antigenicity of tumor cells.
Focused microarrays were effective for testing and vali-
dating a candidate protein. This type of array provides a
complementary follow-up to broad screening arrays. The
validation of immunoreactivity using focused microarrays
was illustrated with the protein hK11. The hK11 (also
known as hippostatin) is a member of the kallikrein family
of secreted serine proteases, which includes PSA (hK3). In
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previous work, hK11 mRNA was found to be over-expressed
in 43/66 (65%) of prostate cancer tissue samples [28], and
isoform 2 protein was shown to have an increased abun-
dance in the serum of 60% of men with prostate cancer
compared with normal [24]. Over-expression in the tumor
environment could be responsible for the generation of an
immune response against the protein, as observed in this
work. We only observed immunoreactivity against isoform 2
(known as the prostate type), and not isoform 1 (brain type),
which may indicate that only isoform 2 is over-expressed in
the tumor, consistent with their previously observed tissue
specificities.
One of the limitations of the focused-array validation
method is the need for recombinant proteins. Since the em-
phasis of this work was advancing the technology and better
characterizing the overall immunoreactivity of prostate can-
cer, we demonstrated the focused array approach on a candi-
date for which recombinant versions were readily available.
Figure 4. Microarray screening of hK11 immunoreactivity. Microarrays were printed with the pattern given in (E). Representative images
are given of incubations with (A) the positive control anti-hK11 antibody; (B) buffer; (C) serum from a cancer patient; and (D) serum from a
control subject. The brightness of each spot indicates the level of antibody binding to that spot, and white pixels indicate saturation of
detector response. (F) Distributions of the reactivity with hK11 isoform 2 in the indicated sample classes. The box indicates the upper and
lower quartiles, the horizontal line the median, and the vertical lines the range. The numbers above each box indicate the number of out-
liers for each class. (G) Receiver-operator characteristic curve analysis of hK11 isoform 2 in distinguishing all prostate cancer patient sam-
ples from the control samples.
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
Proteomics Clin. Appl. 2007, 1, 494–505 505
Other proteins identified by MS/MS were good candidates
for further study, based on their previous associations with
prostate cancer or cancers in general. Our future validation
studies will focus on proteins identified in fresh experiments
with the new methods of separation suggested above, since
those new methods will provide more precise leads on the
candidate proteins. In order to study future candidates effi-
ciently, it may be valuable to have a high-throughput protein
expression system, for example using on-chip translation of
selected sequences [29]. However, immunoreactivity may
only be present in proteins taken directly from cell lines or
tumor tissue, so it may be necessary to use proteins purified
from those materials.
In summary, this work has demonstrated an effective
strategy for profiling patterns of immunoreactivity and for
identifying tumor antigens using natural protein micro-
arrays. We used the method to reveal distinct patterns of
immunoreactivity against multiple proteins in prostate can-
cer patients, and focused microarrays of candidate proteins,
which complemented the larger, screening arrays, were use-
ful for validating immunoreactivity against the protein hK11.
This work lays the groundwork for the broader application of
this method for biomarkers of prostate cancer and other
cancers.
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